Of these, the CD45-iodine131 candidate is part of the IOMAB-B phase III clinical trial investigating its use in older AML patients followed by NMA conditioning (NCT02665065) and the CD45-astatine211 or 211^At-BC8-B10 antibody has a phase I/II trial ongoing to determine the optimal dose before allogeneic HSCT in patients with AML/ALL/MDS or mixed-phenotype acute leukemia (NCT03128034). Here, PTPRC is linked to myelodysplastic syndrome.